GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX's novel PEP™ platform technology Phase 1 trial of MBX 4291 is expected to initiate in Q3 2025 In preclinical studies, the active component of MBX 4291 demonstrated a similar activity profile and body weight loss as tirzepatide, an approved weekly GLP-1/GIP co-agonist. In addition, extended duration of action of the active component of MBX 4291 was observed in additional preclinical studies compared to ...